Legal Representation
Attorney
MICHELLE L. ZIMMERMANN
USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 7, 2025 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Nov 7, 2024 | OPPF | T | OPPOSITION PAPERS RECEIVED AT TTAB | Loading... |
| Nov 7, 2024 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Nov 4, 2024 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED | Loading... |
| Oct 21, 2024 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Oct 8, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 8, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 3, 2024 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Sep 18, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 5, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 14, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 14, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 14, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 10, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 10, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 10, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 8, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 8, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 11, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer,
cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations
for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable
genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical
preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T)
cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical
preparations for use in oncology; all of the foregoing to exclude infectious diseases
First Use Anywhere:
Oct 26, 2016
First Use in Commerce:
Oct 26, 2016
Class 042
Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and
development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical
and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells
and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of
genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases,
and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells
(CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell
therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases
First Use Anywhere:
Oct 26, 2016
First Use in Commerce:
Oct 26, 2016
Classification
International Classes
005
042